METHODS FOR REDUCING THE RISK OF AN ADVERSE DRONEDARONE / CALCIUM CHANNEL BLOCKERS INTERACTION IN A PATIENT SUFFERING FROM ATRIAL FIBRILATION
    7.
    发明申请
    METHODS FOR REDUCING THE RISK OF AN ADVERSE DRONEDARONE / CALCIUM CHANNEL BLOCKERS INTERACTION IN A PATIENT SUFFERING FROM ATRIAL FIBRILATION 审中-公开
    降低患者从ATRIAL FIBRILATION引起的不良DRONEDARONE /钙通道阻断剂相互作用的风险的方法

    公开(公告)号:US20120005128A1

    公开(公告)日:2012-01-05

    申请号:US13172336

    申请日:2011-06-29

    摘要: The disclosure relates to a method for managing the risk of dronedarone/calcium channel blockers interaction by using dronedarone or pharmaceutically acceptable salts thereof in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted to reduce the risk of cardiovascular hospitalization, said patients also expecting to receive a calcium channel blockers treatment, by performing the following steps: a—initiate calcium channel blockers treatment at a low dose; b—performing a electrocardiogram (ECG) verification of good tolerability; c—increase of calcium channel blockers dose only if results in step b) are satisfying.

    摘要翻译: 本公开涉及一种通过在阵发性或持续性心房颤动(AF)或心房扑动(AFL)患者中使用决奈达隆或其药学上可接受的盐来控制决奈达隆/钙通道阻滞剂相互作用的风险的方法,最近一次AF / AFL和相关的心血管危险因素,谁是窦性心律或谁将被心脏转移降低心血管住院的风险,表示患者还期望接受钙通道阻滞剂治疗,通过执行以下步骤:a启动钙通道阻滞剂治疗 低剂量; b执行良好耐受性的心电图(ECG)验证; 仅当步骤b)中的结果令人满意时,钙通道阻滞剂的c-增加。